Here, we propose a strategy for the prognostic evaluation of HF due to DCM based on the combination of serum nuclear magnetic resonance (NMR)-based metabolomics with traditional prognostic factors, such as N-terminal pro b-type natriuretic peptide (NT-proBNP) and LVEF. This evidence concerns the gene NPPB and familial dilated cardiomyopathy.